Prokinetic drugs for gastric emptying in critically ill ventilated patients: Analysis through breath testing

J Crit Care. 2015 Jun;30(3):655.e7-13. doi: 10.1016/j.jcrc.2014.12.019. Epub 2015 Jan 7.

Abstract

Purpose: The prupose was to identify, through the BreathID automatic breath-testing device, the best prokinetic therapy to enhance gastric-emptying rate (GER) in ventilated intensive care unit patients.

Materials and methods: This was a prospective, crossover, nonrandomized study. Consecutive ventilated patients who could be fed enterally and expected to require 5 days of ventilation were included. (13)C-labeled-acetate in 100 mL Osmolite (BreathID; Exalenz Bioscience Ltd, Jerusalem, Israel) was administered intragastrically and followed by a 4-hour continuous recording of expiratory (13)CO2 by the BreathID. Prokinetics were changed daily: (1) baseline (no prokinetic), (2) intravenous (IV) metoclopramide (10 mg every 6 hours), (3) IV metoclopramide (10 mg every 6 hours) and continuous low-dose erythromycin (10 mg/h), (4) IV continuous low-dose erythromycin alone (10 mg/h), and (5) IV bolus erythromycin (200 mg every 12 hours). Gastric-emptying rate was assessed by the percentage dose recovered (PDR)-change from time 0 of the recording in the ratio of (13)CO2/(12)CO2 in exhaled gases (%/h). We used PDR peak values and time to peak (minutes to reach PDR peak) to express GER.

Results: In the first 17 patients (group A), baseline GER measurements preceded prokinetic therapy. In the subsequent 14 patients (group B), 2 prokinetic regimens preceded baseline. No order-time effect was observed, justifying pooled analysis of all 31 patients. Combined metoclopramide-continuous low-dose erythromycin yielded significantly higher PDR peak and shorter time to peak vs baseline (P = .0001, P = .005, respectively). The PDR peak was also significantly higher from baseline during continuous low-dose administration of erythromycin alone (P = .004). Metoclopramide alone did not improve GER significantly.

Conclusions: Combined metoclopramide-continuous low-dose erythromycin was found to be the best protocol in the current study to increase GER in ventilated patients. It should be tested as a first-line prokinetic therapy in ventilated patients with poor gastric emptying in further randomized controlled studies. The breath-test device presented in this study can be a user-friendly and practical method to monitor GER, enabling individual tailoring of prokinetic therapy. Further studies to explore its utility are warranted.

Keywords: Breath tests; Critically ill; Gastric emptying; Gastroparesis; Prokinetics; Ventilated patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breath Tests
  • Carbon Isotopes
  • Critical Care
  • Critical Illness / therapy
  • Cross-Over Studies
  • Enteral Nutrition*
  • Erythromycin / pharmacology*
  • Female
  • Gastric Emptying / drug effects*
  • Gastrointestinal Agents / pharmacology*
  • Humans
  • Israel
  • Male
  • Metoclopramide / pharmacology*
  • Middle Aged
  • Prospective Studies
  • Respiration, Artificial
  • Sodium Acetate

Substances

  • Carbon Isotopes
  • Gastrointestinal Agents
  • Sodium Acetate
  • Erythromycin
  • Metoclopramide